Filing and reporting period
The supplied filing is Flora Growth Corp.’s unaudited Form 10-Q for the three months ended March 31, 2024—not a filing identified as Zerostack Corp. Flora describes its business as cannabis and pharmaceutical distribution and consumer brands, including JustCBD, Vessel and Phatebo. Amounts below are U.S. dollars unless stated otherwise.
Financial performance and position
- Revenue: $18.0 million, down 6.7% from $19.3 million in Q1 2023. Commercial and wholesale sales increased to $11.3 million from $8.0 million; house-of-brands sales declined to $8.0 million from $13.8 million.
- Gross profit and margin: $3.9 million versus $5.3 million; margin was approximately 21.4%, compared with 27.7% in Q1 2023, calculated from reported revenue and gross profit. Management attributed the margin decline primarily to sales mix, with greater contribution from lower-margin pharmaceutical distribution.
- Loss: Operating loss was $2.5 million, compared with $2.4 million. Net loss from continuing operations was $3.4 million versus $3.2 million; total net loss was $3.4 million versus $3.9 million, which included $0.7 million of discontinued-operation losses in 2023. Basic loss per share was $0.38 versus $0.58 attributable to Flora in Q1 2023.
- Adjusted EBITDA: Loss of $1.5 million versus a loss of $0.8 million. This is a company-defined non-GAAP measure and may not be comparable with similarly named measures elsewhere.
- Cash flow: Operating cash outflow was $1.3 million, improved from $4.3 million. Financing provided $1.2 million, mainly from German credit-facility borrowings; investing used $0.1 million. Cash and restricted cash totaled $4.2 million at quarter-end, down from $4.4 million at December 31, 2023.
- Liquidity and debt: Working capital was $2.4 million. Current liabilities were $19.3 million versus current assets of $21.8 million. Debt was $3.1 million, due within 12 months, under German facilities bearing rates of 5.45%–6.44%. Total liabilities were $21.1 million; shareholders’ equity was $3.1 million.
- Other balance-sheet items: Inventory was $9.2 million, including $8.2 million of finished goods. Contingencies were $6.6 million, including $4.1 million for a German legal dispute and $2.5 million for estimated sales taxes.
Changes, outlook and material matters
- Management reported cost reductions, including lower corporate headcount and consulting and management fees, but said operating losses and negative operating cash flow are expected to continue. The filing states that available cash is insufficient to fund growth while meeting obligations and that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after issuance. Additional financing is necessary; availability and terms are uncertain.
- Florida stop-sale orders affected Just Brands products. The company estimated a $0.7 million adverse revenue impact in Q1 and $1.9 million of affected inventory at March 31. A May 7, 2024 settlement required removal of the affected products from Florida, payment of $60,500 in legal fees and a five-year revocation of Just Brands’ Florida food permit.
- A $0.9 million impairment was recorded for Vessel-related lease right-of-use assets and property and equipment, following plans to exit a Florida warehouse lease and seek a facility elsewhere.
- A German court ordered payment of $3.0 million plus interest and 83% of legal fees in a dispute; Flora appealed and recorded a $4.1 million provision, matched by an indemnification receivable. A separate Just Brands acquisition-related claim seeks shares and $38.0 million; the company recorded $1.5 million of contingent consideration based on its estimate of the share value.
- After quarter-end, Flora closed an April offering of 1.7 million shares at $1.90 per share, reporting approximately $2.8 million net proceeds. It also established an at-the-market program of up to $3.8 million, with no sales reported as of the filing. A proposed TruHC Pharma acquisition was structured for 2,770,562 shares: 2,135,199 shares were issued in April, with the remaining 635,363 subject to shareholder approval.
- No quantitative operating guidance is provided. Management’s stated priorities include cost reductions, growth sufficient to cover overhead, financing, and pursuing strategic partnerships and acquisitions. Risks include regulatory changes, product demand and acceptance, litigation, financing needs and the possibility of dilution.
- Management concluded disclosure controls were effective as of March 31, 2024, and reported no material change in internal control over financial reporting. Flora said it regained Nasdaq audit-committee composition compliance after a May 2 appointment.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Flora Growth Corp. (Nasdaq: FLGC), not Zerostack Corp.
- Review the going-concern disclosure, near-term debt maturities and the company’s financing needs, including the effect of subsequent equity issuance and potential ATM sales.
- Assess the status and possible outcomes of the appealed German judgment, indemnification recovery, Just Brands acquisition-related claim, sales-tax provisions and Florida regulatory settlement.
- Evaluate the Florida product restrictions, affected inventory and effect on future JustCBD and related-brand sales.
- Check the filing’s reported comprehensive-loss figures: the statement lists net loss of $3.374 million and foreign-currency translation loss of $27,000, but reports comprehensive loss of $3.347 million; the figures do not reconcile arithmetically and should be confirmed against the filed statements.